arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Gossamer Bio, Inc.

GOSS
$0.18 0.00 (+1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
46
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Gossamer Bio, Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $42.1M
Dividend Yield
Revenue Growth 71.5%
Op. Margin -264.6%
ROIC 21.9%
FCF / Share $-0.17
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.95M
↑ +71.5%
Net Income Profit after all expenses
$-46.66M
↓ -27.4%
Operating Margin Operating profit as % of sales
-264.6%
↑ +20.7% 0th
FCF / Share Free cash flow per share
$-0.17
↑ +5.6%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
100
Financial Health
25
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters